In this episode of the Oncology Brothers podcast, we took a deeper dive into the evolving landscape of CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Joined by esteemed oncologists Dr. Sara Tolaney from Dana-Farber Cancer Institute and Dr. Adam Brufsky from UPMC Hillman Cancer Center, the discussion focused on real-world scenarios involving adjuvant and metastatic settings.
Key topics included:
• The recent updates from the MonarchE and NATALEE trials, highlighting the approval of abemaciclib and ribociclib.
• Strategies for selecting the right adjuvant treatment for high-risk patients, including dosing considerations and side effect management.
• Insights into managing common toxicities associated with CDK4/6 inhibitors, such as diarrhea and QTc prolongation.
• The role of CDK4/6 inhibitors in patients with visceral involvement and the implications of using these therapies in the metastatic setting.
Whether you're a healthcare professional or someone interested in the latest advancements in breast cancer treatment, this episode provided valuable insights and expert opinions on navigating complex treatment decisions.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more episodes and send us your challenging cases for future discussions!
#CDK4/6i #BreastCancer #MonarchE #NATALEE #Abemaciclib #Ribociclib #OncologyBrothers #HRpositive
